Liver/Biliary Disorders News

Physicians treating older veterans with dementia “should consider underlying cirrhosis” and use Fibrosis-4 as a screening tool to uncover reversible factors, such as hepatic encephalopathy, that may be associated with cognitive decline.

Individuals with alcohol-related liver disease and frequent health care utilization were at greater risk for mortality and hospital readmission, respectively, according to a cohort study of alcohol-related hospitalizations in Canada.

Women with concurrent metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease had an 83% greater risk for all-cause mortality than men and those with ALD alone had 160% greater risk, data showed.

A $37 million study led by Newcastle University, University of Edinburgh and Boehringer Ingelheim is underway to address the “urgent need” for anti-scarring therapies for individuals with liver disease.

Incidence of new portal vein thrombosis was higher after transarterial chemoembolization for hepatocellular carcinoma compared with microwave or radiofrequency ablation, although researchers reported no clinically significant sequalae.

Vibration-controlled transient elastography and serum-based noninvasive tests show a significant discrepancy in detecting liver fibrosis, according to study findings published in Obesity.

Chronic hepatitis B virus infection was positively linked with severe hepatic necroinflammation in children with metabolic dysfunction-associated steatotic liver disease but did not appear to affect hepatic fibrosis, according to data.

Topline data from the phase 2b FASCINATE-2 trial showed “statistically significant improvement” for denifanstat in biopsy-confirmed nonalcoholic steatohepatitis with stage 2 or stage 3 fibrosis at 52 weeks, Sagimet Biosciences announced.

Screening for liver fibrosis was associated with improved self-reported alcohol consumption, diet, exercise and weight after 6 months among patients at risk for liver disease, with lifestyle changes persisting through 2 years.

Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists were associated with lower risk for cardiovascular events in type 2 diabetes, with or without metabolic dysfunction-associated steatotic liver disease.